Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07544966
PHASE4

Teen Vulnerability to Irritability: Brain and Estrogen Changes

Sponsor: University of North Carolina, Chapel Hill

View on ClinicalTrials.gov

Summary

Purpose: Risk of severe psychopathology increases dramatically during adolescence, especially for females. Changes in ovarian steroids across the menstrual cycle produce windows of vulnerability to mood disturbances, particularly during the abrupt withdrawal of estradiol (E2) and progesterone (P4) prior to menses onset. Irrefutable evidence links stress with affective symptoms, potentially mediated by E2-related modifications of frontolimbic connectivity and prefrontal gamma-aminobutyric acid (GABA) inhibitory signaling. The primary objective of this project is to empirically test the impact of E2 and P4 change on vulnerable brain networks associated with irritability and other depressive symptoms in female adolescents at risk of suicide. Participants: The investigators will enroll 50 female adolescents ages 12-16 who are at risk of suicide (i.e., moderate depressive symptoms), and are eligible to receive oral contraceptives and undergo MRI imaging. Procedure: Using a randomized, placebo-controlled, cross-over design, participants will be studied under two conditions: 8 weeks of E2 and P4 stabilization (continuous combined oral contraceptive (COC) to prevent perimenstrual withdrawal) and 8 weeks of placebo, with a 1-month washout after each condition. Each condition will include: 1) daily samples of E2 and P4 urinary metabolites, 2) daily symptom ratings(e.g., irritability, negative affect and suicidal thoughts and behaviors (STBs)), and 3) a neuroimaging session with MRI and magnetic resonance spectroscopy (MRS).

Official title: Neurobiological Mechanisms of Susceptibility to Estradiol Fluctuation in Female Adolescents at Risk of Suicide: An Experimental Approach.

Key Details

Gender

FEMALE

Age Range

12 Years - 16 Years

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-06-01

Completion Date

2029-04

Last Updated

2026-04-22

Healthy Volunteers

Yes

Interventions

DRUG

Kurvelo

Kurvelo®: 30mcg ethinyl estradiol (EE) and 0.15mg levonorgestrel (LNG), a synthetic estrogen and progestin, respectively.

DRUG

Placebo COC

Placebo pills from the Kurvelo® packages (cut from package to maintain blinding).

Locations (2)

Biomedical Research Imaging Center (BRIC) at UNC

Chapel Hill, North Carolina, United States

Carolina Crossing

Chapel Hill, North Carolina, United States